- Sections
- C - Chimie; métallurgie
- C07D - Composés hétérocycliques
- C07D 209/12 - Radicaux substitués par des atomes d'oxygène
Détention brevets de la classe C07D 209/12
Brevets de cette classe: 637
Historique des publications depuis 10 ans
|
61
|
52
|
45
|
48
|
63
|
28
|
39
|
27
|
45
|
11
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Bristol-myers Squibb Company | 5080 |
16 |
| Vertex Pharmaceuticals Incorporated | 1581 |
15 |
| Achillion Pharmaceuticals, Inc. | 176 |
14 |
| Janssen Pharmaceuticals, Inc. | 399 |
11 |
| The Johns Hopkins University | 5377 |
9 |
| BioCryst Pharmaceuticals, Inc. | 170 |
9 |
| Katholieke Universiteit Leuven | 1035 |
9 |
| FUJIFILM Corporation | 27102 |
8 |
| California Institute of Technology | 3884 |
8 |
| Novartis AG | 11238 |
7 |
| F. Hoffmann-La Roche AG | 7958 |
6 |
| Toyama Chemical Co., Ltd. | 114 |
6 |
| Versicolor Technologies, LLC | 10 |
6 |
| The Regents of the University of California | 18943 |
5 |
| Wyeth LLC | 691 |
5 |
| The Board of Trustees of the University of Illinois | 2623 |
5 |
| Jiangsu Hengrui Medicine Co., Ltd. | 780 |
5 |
| Medivir AB | 142 |
5 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 588 |
5 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
5 |
| Autres propriétaires | 478 |